Hakutulokset - David D. Stenehjem

  • Näytetään 1 - 8 yhteensä 8 tuloksesta
Tarkenna hakua
  1. 1
    Panobinostat for the treatment of multiple myeloma: the evidence to date

    Panobinostat for the treatment of multiple myeloma: the evidence to date Tekijä Sunil Sharma, Hanna Bailey, David D. Stenehjem

    Julkaistu 2015
    Hae kokoteksti Hae kokoteksti
    Revisão
    Lisää suosikkeihin
    Tallennettuna:
  2. 2
    PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer

    PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer Tekijä David D. Stenehjem, Dao Tran, Michael Nkrumah, Shilpa Gupta

    Julkaistu 2018
    Hae kokoteksti Hae kokoteksti
    Revisão
    Lisää suosikkeihin
    Tallennettuna:
  3. 3
    Tumor mutational burden in lung cancer: a systematic literature review

    Tumor mutational burden in lung cancer: a systematic literature review Tekijä Connor Willis, Michelle Fiander, Dao Tran, Beata Korytowsky, John-Michael Thomas, Florencio Calderon, Teresa Zyczynski, Diana Brixner, David D. Stenehjem

    Julkaistu 2019
    Hae kokoteksti Hae kokoteksti
    Revisão
    Lisää suosikkeihin
    Tallennettuna:
  4. 4
    Cancer incidence in immunocompromised patients: a single-center cohort study

    Cancer incidence in immunocompromised patients: a single-center cohort study Tekijä Sabrina Ilham, Connor Willis, Kibum Kim, Karen Chung, Brenda Wood, Malinda S. Tan, Chia Jie Tan, Danielle Nguyen, Diana Brixner, David D. Stenehjem

    Julkaistu 2023
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  5. 5
    Real-world outcomes of immunotherapy–based regimens in first-line advanced non-small cell lung cancer

    Real-world outcomes of immunotherapy–based regimens in first-line advanced non-small cell lung cancer Tekijä David Waterhouse, Jenny Lam, Keith A. Betts, Lei Yin, Sophie Gao, Yong Yuan, John Hartman, Sumati Rao, Solomon J. Lubinga, David D. Stenehjem

    Julkaistu 2021
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  6. 6
    Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinoma

    Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinoma Tekijä James A. Kuzman, David D. Stenehjem, Joseph A. Merriman, Archana M. Agarwal, Shiven B. Patel, Andrew W. Hahn, Anitha Alex, Dan Albertson, David Gill, Neeraj Agarwal

    Julkaistu 2017
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  7. 7
    Circulating immune cell phenotype dynamics reflect the strength of tumor–immune cell interactions in patients during immunotherapy

    Circulating immune cell phenotype dynamics reflect the strength of tumor–immune cell interactions in patients during immunotherapy Tekijä Jason I. Griffiths, Pierre Wallet, Lance Pflieger, David D. Stenehjem, Xuan Liu, Patrick A. Cosgrove, Neena A. Leggett, Jasmine A. McQuerry, Gajendra Shrestha, Maura Rossetti, Gemalene Sunga, Philip J. Moos, Frederick R. Adler, Jeffrey T. Chang, Sunil Sharma, Andrea H. Bild

    Julkaistu 2020
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  8. 8
    American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer

    American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer Tekijä Gary H. Lyman, Marc Carrier, Cihan Ay, Marcello Di Nisio, Lisa K. Hicks, Alok A. Khorana, Andrew D. Leavitt, Agnes Y.Y. Lee, Fergus Macbeth, Rebecca L. Morgan, Simon Noble, Elizabeth A. Sexton, David D. Stenehjem, Wojtek Wiercioch, Lara A Kahale, Pablo Alonso‐Coello

    Julkaistu 2021
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:

Työkalut: